A look at how drug developers fare after floating in Europe suggests why many tread a path to the US and a Nasdaq listing.
Investors are piling into biotech IPOs, but the track record of previous years' new issues shows how hard it is to pick winners.
Drug developers raised a record $4.5bn in IPOs in the third quarter, and investor support for biopharma shows little sign of waning.
Curevac’s market cap has ballooned almost fivefold since floating, sending the mRNA company into the record books.
Medtechs going public in 2020 raised a decent amount of cash, but have had a turbulent time of it since.
After a brief pause in the first quarter flotations have come flooding back, with drug developers raising almost $5bn so far this year.
Several young drug developers managed to float in the first quarter, but new issues dried up in March when coronavirus infected the markets. Is the game back on?
The device sector enjoyed a mid-year IPO bonanza, but after getting away the class of 2019 had a torrid time.
A stock market rebound created a strong finish for biopharma flotations in 2019, with four $100m-plus floats, led by Phathom Pharmaceuticals.